Please login to the form below
Keytruda
This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda receives FDA approval for advanced endometrial cancer
The trial results showed that patients receiving Keytruda demonstrated an objective response rate of 46%. ... an objective response rate of 46% for certain patients with advanced endometrial carcinoma … treated with Keytruda.”.
Latest news
-
Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients
with Keytruda, which supplemented standard chemotherapy prior to surgery, with a follow-up treatment using Keytruda after surgery. ... After their surgery, patients continued to receive either Keytruda without chemotherapy, or placebo.
-
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma. ... The results presented demonstrated that the combination of Lenvima plus Keytruda
-
Keytruda gains eighth FDA approval this year
Keytruda’s first approval seven years ago was also in melanoma, said Dr Scot Ebbinghaus from Merck Research Laboratories. ... Since then, we have built on this foundation in melanoma and have expanded the use of Keytruda into earlier stages of this
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s Keytruda (pembrolizumab), advanced TNBC remains a very difficult cancer to treat.
-
Merck receives first breast cancer approval in Europe for Keytruda
Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy. ... Patients in all 27 European Union member states plus Iceland, Lichtenstein, Norway and Northern Ireland
More from news
Approximately 174 fully matching, plus 283 partially matching documents found.
Latest Intelligence
-
Putting commercial intelligence at the heart of strategy
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
-
20 for 2020 – Five pharma companies to watch
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
-
25 Women Leaders in UK Healthcare
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
-
Immuno-oncology in 2019: the rapid evolution continues
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
-
BMS appoints new commercial leader, Davies joins Eisai and more
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
-
18 SWITCHED ONcology: The Big Communication
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
-
A stumble, but not a fall – what’s next for Opdivo?
Impressively, Opdivo consistently outperformed Merck &Co.'s ($MRK) Keytruda (pembrolizumab), racking up $1.58 billion in sales during the first half of 2016 compared to $563 million earned by its main ... Rubbing salt into BMS’s wounds, Merck's
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Scientists discover new approach to treat brain tumours
- Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program
- UK trial of fourth vaccine dose shows increased protection against COVID-19
- Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
- BMA appoints two internal candidates to share the role of chief executive officer
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Recognising HIV Vaccine Awareness Day
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- How scientific storytelling can help Pharma cut through the noise
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- GSK accused of delaying generic Seroxat in UK
- Christian Schade joins Aprea AB
- Assessing the value of interim analyses in clinical trials
- MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
- How scientific storytelling can help Pharma cut through the noise
- Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...
